Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (9779)	5/4/1999 10:59:00 PM
From: Robert K.	Respond to of 17367

Dr Blue, I can count far more indications than you. :-) My old list >Yahoo 945

To: Bluegreen who wrote (9779)	5/4/1999 11:11:00 PM
From: Edscharp	Read Replies (1) \| Respond to of 17367

Like many of you, I am currently being inundated with Annual Reports from the various companies I'm invested or interested in. In perusing these Annual Reports I'm struck by the number of companies that are working on remedies for psoriasis. Aside from Xoma's hu1124, Vertex has just completed Phase I trial of their IMPHD inhibitor (VX-497), Ligand's Panretin capsules are currently in PII. Isis will begin clinical trials with ISIS 2302, a topical application for psoriasis, and ICOS' product ICM3 is currently in PI. Note that these are only the companies that I'm familiar with. I imagine there are quite a few more doing work in the area of psoriasis. If your one of the people who has psoriasis the future is looking bright for you. If your invested in a company strongly dependent on a remedy for this malady be aware that the competition in this arena promises to very heavy. Unless hu1124 proves to be cheaper, safer or more effective than other products this could end up being a short-lived product. Of course, none of this really matters if the damn Meningococcemia trial doesn't end soon. George, I'll vote my 1k shares against management. Where do I write in your name for CEO? <g>